CAS 1628805-46-8

IDH-305

CAS : 1628805-46-8

IDH-305: Oral, mutation-specific IDH1 inhibitor, 200x selective for R132 mutants; IC50: 27/28/6.14 nM for R132H/C/WT.

Formule : C₂₃H₂₂F₄N₆O₂

Degré de pureté : 99.68%

Couleur et forme : Solid

Masse moléculaire : 490.45

Ref: TM-T15550

(4R)-4-[(1S)-1-fluoroethyl]-3-(2-{[(1S)-1-[4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl]ethyl]amino}pyrimidin-4-yl)-1,3-oxazolidin-2-one

CAS : 1628805-46-8

Formule : C₂₃H₂₂F₄N₆O₂

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 490.4534

Ref: IN-DA00IKMH

IDH-305

CAS : 1628805-46-8

IDH-305

Degré de pureté : ≥98%

Masse moléculaire : 490.45g/mol

Ref: 54-BUP04418

IDH 305

CAS : 1628805-46-8

IDH 305 is a retinoic acid that is used in the treatment of intrahepatic cholangiocarcinoma (ICC). It has been shown to inhibit cancer cell growth in vitro and in vivo. Retinoic acid binds to cellular retinoic acid receptors, which activate transcription factors that regulate gene expression. The activity of IDH 305 may be due to its ability to inhibit glucose transporters, leading to decreased uptake of glucose into cells and inhibition of histone methylation and DNA synthesis.

Formule : C₂₃H₂₂F₄N₆O₂

Degré de pureté : Min. 95%

Masse moléculaire : 490.45 g/mol

Ref: 3D-DQC80546